Morgan Stanley’s Neuropace NPCE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $28.8M | Buy |
2,585,073
+54,453
| +2% | +$607K | ﹤0.01% | 2451 |
|
|
2025
Q1 | $31.1M | Buy |
2,530,620
+38,790
| +2% | +$477K | ﹤0.01% | 2252 |
|
|
2024
Q4 | $27.9M | Sell |
2,491,830
-2,511
| -0.1% | -$28.1K | ﹤0.01% | 2418 |
|
|
2024
Q3 | $17.4M | Buy |
2,494,341
+23,199
| +0.9% | +$162K | ﹤0.01% | 2930 |
|
|
2024
Q2 | $18.7M | Sell |
2,471,142
-12,841
| -0.5% | -$97.1K | ﹤0.01% | 2740 |
|
|
2024
Q1 | $32.8M | Sell |
2,483,983
-2,437,449
| -50% | -$32.2M | ﹤0.01% | 2165 |
|
|
2023
Q4 | $50.7M | Buy |
4,921,432
+2,521,716
| +105% | +$26M | ﹤0.01% | 2435 |
|
|
2023
Q3 | $23.3M | Buy |
2,399,716
+40,850
| +2% | +$397K | ﹤0.01% | 2290 |
|
|
2023
Q2 | $10.6M | Buy |
2,358,866
+100,850
| +4% | +$453K | ﹤0.01% | 3100 |
|
|
2023
Q1 | $10.5M | Buy |
2,258,016
+69,423
| +3% | +$322K | ﹤0.01% | 3100 |
|
|
2022
Q4 | $3.26M | Buy |
2,188,593
+64,990
| +3% | +$96.8K | ﹤0.01% | 4120 |
|
|
2022
Q3 | $7.96M | Buy |
2,123,603
+138,414
| +7% | +$519K | ﹤0.01% | 3199 |
|
|
2022
Q2 | $9.83M | Buy |
1,985,189
+949,405
| +92% | +$4.7M | ﹤0.01% | 3080 |
|
|
2022
Q1 | $8.5M | Buy |
1,035,784
+769,556
| +289% | +$6.32M | ﹤0.01% | 3096 |
|
|
2021
Q4 | $2.68M | Buy |
266,228
+258,570
| +3,376% | +$2.61M | ﹤0.01% | 4337 |
|
|
2021
Q3 | $121K | Buy |
7,658
+66
| +0.9% | +$1.04K | ﹤0.01% | 6265 |
|
|
2021
Q2 | $181K | Buy |
+7,592
| New | +$181K | ﹤0.01% | 6066 |
|